10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

TNFRSF11B antibody - N-terminal region

Rabbit Polyclonal Antibody
Catalog # AI16167

Product Information

Application	WB
Primary Accession	O00300
Other Accession	NM_002546, NP_002537
Reactivity	Human, Mouse, Rat, Rabbit, Pig, Dog, Horse
Predicted	Human, Mouse, Rat, Rabbit, Pig, Dog, Horse
Host	Rabbit
Clonality	Polyclonal
Calculated MW	46026

Additional Information

Gene ID	4982
Alias Symbol	OPG, TR1, OCIF
Other Names	Tumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin, TNFRSF11B, OCIF, OPG
Format	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage	Add 100 ul of distilled water. Final anti-TNFRSF11B antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
Precautions	TNFRSF11B antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	TNFRSF11B
Synonyms	OCIF, OPG
Function	Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.

Cellular Location	Secreted.
Tissue Location	Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung


Background

Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.

References

Simonet W.S.,et al.Cell 89:309-319(1997).
Yasuda H.,et al.Endocrinology 139:1329-1337(1998).
Morinaga T.,et al.Eur. J. Biochem. 254:685-691(1998).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Suzuki Y.,et al.Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.

Images



WB Suggested Anti-TNFRSF11B Antibody Titration: 1.25µg/ml
ELISA Titer: 1:312500
Positive Control: HepG2 cell lysate

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.